Apararenone

Apararenone (INN; development code MT-3995) is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi Tanabe Pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Apararenone (INN; development code MT-3995) is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi Tanabe Pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis. It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication.

Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (K i < 50 nM), the receptor for aldosterone. As of 2017, it is in phase II clinical trials.

Apararenone (INN; development code MT-3995) is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi Tanabe Pharma for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis. It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication.

Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor (K i < 50 nM), the receptor for aldosterone. As of 2017, it is in phase II clinical trials.

See also

Esaxerenone Finerenone

Apararenone - AdisInsight

Text derived from https://en.wikipedia.org/w/index.php?oldid=1363768055 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.